Lycia Therapeutics (LYCA) 10% Owner L.P. Buys $1.4M of Stock
Key Points
- Venrock Healthcare's purchase of 52,939 shares brings its total ownership to 52,939 shares worth approximately $1.37 million.
- Currently, Lycia Therapeutics trades at around $26.11, which is about 11.3% below its 50-day and 200-day moving averages.
- The company has a market cap of about $1.36 billion and reported trailing twelve-month revenue of approximately $4.44 million.
Since the trade, $LYCA is down 13.0% to date (from the $30 close on Oct 23, 2026).
Get Lycia Therapeutics text alerts
We text you when insiders, Congress, analysts or big funds move on $LYCA.
By entering your mobile number and tapping the sign-up button, you provide express written consent to receive recurring automated text messages from TradeTexts at that number, including stock alerts about SEC filings, insider and congress trades, analyst ratings, hedge fund moves, and earnings results. Consent is not a condition of any purchase. Message frequency varies. Messages are not investment advice. Message and data rates may apply. Reply HELP for help and STOP to opt out at any time. See our Terms and Privacy Policy.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated Lycia Therapeutics, Inc. alert may contain errors. Disclosures
On October 23, 2026, Venrock Healthcare Capital Partners III, L.P. bought 52,939 shares of Lycia Therapeutics, Inc. at a price of $25.91 per share, totaling about $1.37 million. This purchase was filed with the SEC and reflects Venrock's ongoing investment strategy in the healthcare sector.
LYCA
Lycia Therapeutics, Inc.
Venrock Healthcare Capital Partners III, L.P. vs. the S&P 500
Hypothetical returns from Venrock Healthcare Capital Partners III, L.P.'s disclosed trades, not real profit or advice. How we model this.
What Changed in Venrock Healthcare's Lycia Therapeutics Position
Venrock Healthcare acquired 52,939 shares, increasing its stake to 52,939 shares. The total value of this transaction was approximately $1.37 million. This move shows confidence in Lycia's potential in the biotechnology industry, especially as it develops treatments for autoimmune and inflammatory diseases.
Lycia Therapeutics, Inc. Stock Down 9.5%
Currently, Lycia Therapeutics trades at approximately $26.11, which is about 11.3% below its 50-day and 200-day moving averages of $29.43. The stock is also 28.4% lower than its 52-week high of $36.49, but it remains 17.7% above its 52-week low of $22.19. This positioning may attract interest from investors looking for opportunities in a potentially undervalued stock.
Recent Earnings
Lycia Therapeutics reported trailing twelve-month revenue of approximately $4.44 million. The company is still in the early stages of its development pipeline, focusing on therapies that target disease-causing extracellular proteins.
About Lycia Therapeutics
Lycia Therapeutics, Inc. is a biotechnology company based in South San Francisco, CA. It specializes in discovering and developing therapies aimed at degrading proteins that cause diseases, particularly for autoimmune and allergic conditions. The firm's LYTAC platform is a key technology in its efforts to create targeted therapeutics.
Bottom Line
Investors may want to keep an eye on Lycia Therapeutics as it continues to develop its product pipeline. Venrock's recent purchase could indicate confidence in the company's future prospects. The next earnings report may provide further insights into its performance and strategic direction.
Related Filing Alerts
Source: Venrock Healthcare Capital Partners III, L.P.'s Form 4 filing on $LYCA (Oct 23, 2026). Written by software, not financial advice. How we make alerts